Esophageal cancer chemotherapy drug hydroxycamptothecin comments

By | January 22, 2012

Of HCPT after 1996 from extensive research to clinical pharmacology.Hydroxycamptothecin comments, Guangzhou, Zhongshan Medical University Cancer Hospital with HCPT alone administration for 5 days I clinical study, the maximum tolerated dose was 20mg/ml, for 5 days, dose-limiting toxicity is hematologic toxicity, Recommended dose combination therapy 10–12mg/ml, for 5 days. Number of cases of gastrointestinal cancer applications up to HCPT, gastric cancer, colorectal cancer and esophageal cancer programs containing HCPT, DDP ,5-FU / CF, MMC and ADM based, mainly involved in the treatment of primary liver cancer.
Hydroxycamptothecin comments, followed by lung cancer , small cell lung cancer program HCPT + VP-16 or HCPT + DDP or 3 drug combination, non-small cell lung cancer program CTX + DDP ten HCPT or MMC + DDP + HCPT. HCPT treatment of malignant pleural effusion, breast cancer , choriocarcinoma, ovarian cancer has also been reported.
The above study shows HCPT diseases effectively. There are reports of lead far CPT chemotherapeutic treatment of advanced esophageal squamous cell carcinoma, 30 cases of advanced esophageal cancer patients with HCPT4.68–7.04mg/ml (median dose of 5.6mg/ml, intravenous infusion for 3 consecutive days; DDP58 .5100mg/ml (median dose of 70mg/ml, day 1, intravenous infusion; 21 days for a period of at least 2 cycles of treatment.
Hydroxycamptothecin comments, the results show the 28 patients were evaluable for response rate was 42.9% (12/28), the main toxicity was bone marrow suppression, and other side effects include nausea, vomiting, diarrhea, transient liver and kidney function with mild damage. No heart, lung toxicity. III / N degrees from the cells, nausea, vomiting, thrombocytopenia, diarrhea rates were 28.7%, 21.8%, 13.9% and 2.0%. Show chemotherapeutic camptothecin from the good effect of lead treatment of esophageal cancer, toxicity can be tolerated.

Leave a Reply

Your email address will not be published. Required fields are marked *